{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:33:15Z","timestamp":1779161595540,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Louisville Center for Predictive Medicine BIO-Imaging and Animal Models Core Facilities"},{"name":"University of Louisville Center for Predictive Medicine (M.B.L)"},{"name":"University of Louisville School of Medicine"},{"DOI":"10.13039\/100000888","name":"W.M. Keck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000888","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Commonwealth of Kentucky Research Challenge Trust Fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.07.015","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T22:00:23Z","timestamp":1405720823000},"page":"5035-5040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant"],"prefix":"10.1016","volume":"32","author":[{"given":"Gunes","family":"Dinc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrod M.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esma S.","family":"Yolcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Lawrenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haval","family":"Shirwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2014.07.015_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.10.1.35","article-title":"Yersinia pestis\u2014etiologic agent of plague","volume":"10","author":"Perry","year":"1997","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2014.07.015_bib0010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3855\/jidc.2030","article-title":"Developing live vaccines against plague","volume":"5","author":"Sun","year":"2011","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ccc.2013.03.015","article-title":"Biowarfare and bioterrorism","volume":"29","author":"Christian","year":"2013","journal-title":"Crit Care Clin"},{"issue":"8","key":"10.1016\/j.vaccine.2014.07.015_bib0020","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1086\/428617","article-title":"Risk of person-to-person transmission of pneumonic plague","volume":"40","author":"Kool","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.015_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199709043371004","article-title":"Multidrug resistance in Yersinia pestis mediated by a transferable plasmid","volume":"337","author":"Galimand","year":"1997","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2014.07.015_bib0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-695X.1995.tb00196.x","article-title":"A new improved sub-unit vaccine for plague: the basis of protection","volume":"12","author":"Williamson","year":"1995","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1389-0344(01)00101-0","article-title":"Recent developments in adjuvants for vaccines against infectious diseases","volume":"18","author":"O\u2019Hagan","year":"2001","journal-title":"Biomol Eng"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.015_bib0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/1044-579X(95)90007-1","article-title":"Selection of potent immunological adjuvants for vaccine construction","volume":"6","author":"McElrath","year":"1995","journal-title":"Semin Cancer Biol"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2014.07.015_bib0045","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","article-title":"Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine","volume":"16","author":"Heath","year":"1998","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2014.07.015_bib0050","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1016\/S0264-410X(03)00379-7","article-title":"Protective efficacy of a fully recombinant plague vaccine in the guinea pig","volume":"21","author":"Jones","year":"2003","journal-title":"Vaccine"},{"issue":"Pt 7","key":"10.1016\/j.vaccine.2014.07.015_bib0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1099\/jmm.0.037960-0","article-title":"The natural history and incidence of Yersinia pestis and prospects for vaccination","volume":"61","author":"Williamson","year":"2012","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/14760584.7.2.209","article-title":"Current challenges in the development of vaccines for pneumonic plague","volume":"7","author":"Smiley","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2014.07.015_bib0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3855\/jidc.1999","article-title":"Role of immune response in Yersinia pestis infection","volume":"5","author":"Amedei","year":"2011","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.vaccine.2014.07.015_bib0315","unstructured":"Pitt, M.A.M.a.C.o.P.f.P.V.W. Non-human primates as a model for pneumonic plague. 2004; Available from: http:\/\/www.fda.gov\/cber\/minutes\/plague101304t.pdf."},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.015_bib0075","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4269\/ajtmh.1998.58.793","article-title":"Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice","volume":"58","author":"Anderson","year":"1998","journal-title":"Am J Trop Med Hyg"},{"issue":"49","key":"10.1016\/j.vaccine.2014.07.015_bib0080","doi-asserted-by":"crossref","first-page":"7748","DOI":"10.1016\/j.vaccine.2010.09.062","article-title":"Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)","volume":"28","author":"Fellows","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.015_bib0085","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.00185-06","article-title":"Gamma interferon: tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection","volume":"74","author":"Parent","year":"2006","journal-title":"Infect Immun"},{"issue":"52","key":"10.1016\/j.vaccine.2014.07.015_bib0090","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1016\/j.vaccine.2008.09.063","article-title":"Antibodies and cytokines independently protect against pneumonic plague","volume":"26","author":"Kummer","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vaccine.2010.08.099","article-title":"TNFalpha and IFNgamma contribute to F1\/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague","volume":"29","author":"Lin","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.015_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/IAI.61.1.23-31.1993","article-title":"Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha","volume":"61","author":"Nakajima","year":"1993","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.015_bib0105","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1128\/IAI.73.11.7304-7310.2005","article-title":"Cell-mediated protection against pulmonary Yersinia pestis infection","volume":"73","author":"Parent","year":"2005","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.015_bib0110","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-08-3141","article-title":"Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors","volume":"69","author":"Sharma","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.015_bib0115","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1158\/0008-5472.CAN-09-4480","article-title":"4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines","volume":"70","author":"Sharma","year":"2010","journal-title":"Cancer Res"},{"issue":"36","key":"10.1016\/j.vaccine.2014.07.015_bib0120","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1016\/j.vaccine.2010.06.073","article-title":"SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model","volume":"28","author":"Sharma","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.yexmp.2005.12.004","article-title":"Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon","volume":"80","author":"Kilinc","year":"2006","journal-title":"Exp Mol Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.015_bib0130","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1074-7613(02)00482-X","article-title":"Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection","volume":"17","author":"Yolcu","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yexmp.2009.01.010","article-title":"ProtEx technology for the generation of novel therapeutic cancer vaccines","volume":"86","author":"Schabowsky","year":"2009","journal-title":"Exp Mol Pathol"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.015_bib0140","doi-asserted-by":"crossref","first-page":"e47123","DOI":"10.1371\/journal.pone.0047123","article-title":"Development of bioluminescent bioreporters for in vitro and in vivo tracking of Yersinia pestis","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.07.015_bib0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-62703-718-1_14","article-title":"Bioluminescent imaging of bacteria during mouse infection","volume":"1098","author":"Warawa","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.015_bib0150","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.4049\/jimmunol.179.11.7295","article-title":"Ex vivo expansion of CD4+CD25+FoxP3+T regulatory cells based on synergy between IL-2 and 4-1BB signaling","volume":"179","author":"Elpek","year":"2007","journal-title":"J Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2014.07.015_bib0155","first-page":"4067","article-title":"A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.015_bib0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2249.1999.00859.x","article-title":"An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model","volume":"116","author":"Williamson","year":"1999","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2014.07.015_bib0165","doi-asserted-by":"crossref","first-page":"e73145","DOI":"10.1371\/journal.pone.0073145","article-title":"CD4(+) T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models","volume":"8","author":"Sharma","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","article-title":"The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice","volume":"212","author":"Martin","year":"1998","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1016\/j.vaccine.2014.07.015_bib0175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"6797","key":"10.1016\/j.vaccine.2014.07.015_bib0180","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/35021239","article-title":"Vaccines against intracellular infections requiring cellular immunity","volume":"406","author":"Seder","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2014.07.015_bib0185","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1128\/IAI.71.9.5178-5187.2003","article-title":"Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice","volume":"71","author":"Su","year":"2003","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2014.07.015_bib0190","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1073\/pnas.0306567101","article-title":"Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses","volume":"101","author":"Bukczynski","year":"2004","journal-title":"Proc Nat Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0195","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4049\/jimmunol.182.2.934","article-title":"Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease","volume":"182","author":"Lin","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/intimm\/dxh371","article-title":"Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells","volume":"18","author":"Myers","year":"2006","journal-title":"Int Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.015_bib0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/15258160152509064","article-title":"Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells","volume":"10","author":"Kim","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0210","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<881::AID-IMMU881>3.0.CO;2-0","article-title":"Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses","volume":"28","author":"Kim","year":"1998","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2014.07.015_bib0215","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.155.7.3360","article-title":"Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28","volume":"155","author":"Hurtado","year":"1995","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.015_bib0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2014.07.015_bib0225","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/CJI.0b013e318177a4ba","article-title":"Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer","volume":"31","author":"Acquavella","year":"2008","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.015_bib0230","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/1535-7163.MCT-09-0820","article-title":"A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2\/neu-expressing malignancies","volume":"8","author":"Bekaii-Saab","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"10.1016\/j.vaccine.2014.07.015_bib0235","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1158\/0008-5472.CAN-12-0257","article-title":"Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies","volume":"72","author":"Karbach","year":"2012","journal-title":"Cancer Res"},{"issue":"39","key":"10.1016\/j.vaccine.2014.07.015_bib0240","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2010.12.062","article-title":"Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0245","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2009.09.127","article-title":"A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity","volume":"28","author":"Schabowsky","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2014.07.015_bib0250","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.162.9.5037","article-title":"Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal","volume":"162","author":"Takahashi","year":"1999","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.015_bib0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0260","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/IAI.01529-06","article-title":"Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection","volume":"75","author":"Philipovskiy","year":"2007","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2014.07.015_bib0265","doi-asserted-by":"crossref","first-page":"e34377","DOI":"10.1371\/journal.pone.0034377","article-title":"Host differences in influenza-specific CD4 T cell and B cell responses are modulated by viral strain and route of immunization","volume":"7","author":"Sundararajan","year":"2012","journal-title":"PLoS One"},{"issue":"4804","key":"10.1016\/j.vaccine.2014.07.015_bib0270","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1126\/science.3107127","article-title":"Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production","volume":"236","author":"Snapper","year":"1987","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.vaccine.2014.07.015_bib0275","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.vaccine.2009.02.016","article-title":"CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague","volume":"27","author":"Amemiya","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2014.07.015_bib0280","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1128\/IAI.71.12.6915-6920.2003","article-title":"Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3","volume":"71","author":"Lefeber","year":"2003","journal-title":"Infect Immun"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2014.07.015_bib0285","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/15216540600746377","article-title":"Complement-mediated phagocytosis\u2014the role of Syk","volume":"58","author":"Tohyama","year":"2006","journal-title":"IUBMB Life"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.015_bib0290","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1128\/IAI.73.11.7142-7150.2005","article-title":"Pathogenesis of Yersinia pestis infection in BALB\/c mice: effects on host macrophages and neutrophils","volume":"73","author":"Lukaszewski","year":"2005","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2014.07.015_bib0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1574-695X.1999.tb01229.x","article-title":"The SCID\/Beige mouse as a model to investigate protection against Yersinia pestis","volume":"23","author":"Green","year":"1999","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.015_bib0300","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.1997.56.471","article-title":"Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis","volume":"56","author":"Anderson","year":"1997","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.015_bib0305","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/IAI.71.4.2234-2238.2003","article-title":"Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis","volume":"71","author":"Hill","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.07.015_bib0310","series-title":"Animals models and correlates of protection for plague vaccines workshop","article-title":"Non-human primates as a model for pneumonic plague","author":"WebsitePitt","year":"2004"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14009414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14009414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T10:20:51Z","timestamp":1689416451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14009414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":62,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14009414"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}